Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
ASTRO bladder RT guideline: TMT strongly recommended (high QoE) as an RC alternative for select cT2-4aN0M0 MIBC; bladder-alone 5500 cGy/20 fx or 6400-6480 cGy/32-36 fx.
ASTRO guideline backs TMT with concurrent radiosensitizing systemic therapy as an RC alternative for select cT2-4aN0M0 MIBC (strong, high QoE). It sets dose, IMRT/VMAT with daily CBCT, and conditional adjuvant RT for (y)pT3-4, (y)pN+ or positive margins. Soft spots: elective nodal RT has no validated RCT vs bladder-only; concurrent IO remains investigational.
read the full digest →Studies · 131
- ASTRO Clinical Practice Guideline: RT for Bladder CancerTMT recommended (strong, high QoE) as alternative to RC for select cT2-4aN0M0 MIBC; bladder-alone 5500 cGy/20 fx or 6400-6480 cGy/32-36 fx.
- Gamma Knife vs LINAC-based radiosurgery for vestibular schwannoma (retrospective review)Local control 98.8%; no difference in new vertigo, gait disturbance or facial palsy with GKRS (n=36) vs LINAC (n=49) SRS for vestibular schwannoma.
- SWOG S1827/MAVERICKRandomized phase III, LS or ES SCLC: PCI 25 Gy/10 fx + MRI vs MRI surveillance alone; no CFFS or OS results in source tweets.
- TORPEdO18% vs 7% 12-mo G-tube dependence/≥20% weight loss (p=0.079), UW-QoL 78.3 vs 77.1 (p=0.56): IMPT not superior to IMRT, locally advanced oropharyngeal SCC.
- PROTEUS5-yr BCR-FS 44%, MFS 71%, CSS 92% at 60-mo median f/u in a real-world high-risk prostate cancer benchmark cohort.
- MARCAP ConsortiumIPD meta-analysis, 10,853 pts: ADT added to RT improved MFS HR 0.83 and OS HR 0.86; dose escalation improved bRFS only.
- STAR-TREC12-mo TME-free survival 78.5% vs 60.6% (HR 1.90) favouring LCCRT over SCRT for organ preservation in mrT1-T3bN0 rectal cancer ≤40 mm.
- Focal Ablation vs IMRT Toxicity (SEER-Medicare)GI toxicity favored focal therapy at 24mo (11.0% vs 21.5%, OR 0.45) but GU toxicity favored IMRT (41.7% vs 29.3%, OR 1.69).
- NRG-GU0053yr DFS 88.6% SBRT vs 92.1% MH-IMRT, superiority rejected (adjusted HR 1.40, 0.91-2.13); bowel and GU toxicity favored SBRT.
- Testosterone recovery post-ADT discontinuation (podcast review)Review of two datasets: 25% of real-world pts recovered T within 12mo; 54% relugolix vs 3% leuprolide at 90d in HERO.
- Moderately hypofractionated partial breast reirradiation40Gy/15fx PBI re-RT after second lumpectomy: 3yr LR-FS, DR-FS and OS all 86%, no grade 3+ late events (N=11).
- NSABP B-35 margin-width analysis10yr IBTR 5.6% vs 4.0% at 1mm cutoff (abs diff 1.6%), 5.3% vs 3.8% at 2mm (abs diff 1.5%).